News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|October 23, 2024

Managing Persistent MDD: Case Studies and Treatment Challenges

Key Takeaways

Gus Alva, MD, DFAPA presents the case of a patient with recurrent MDD, and the panel explores treatment approaches, comments on the condition triggers, and challenges in managing persistent depression.

Episodes in this series

EP. 1 Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP. 1 Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP. 2 Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP. 2 Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP. 3 Commentary on Redefining Depression Management with Updated Treatment Strategies

EP. 3 Commentary on Redefining Depression Management with Updated Treatment Strategies

EP. 4 Navigating Non-Response: A Holistic Approach to Patient Care

EP. 4 Navigating Non-Response: A Holistic Approach to Patient Care

EP. 5 Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP. 5 Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP. 6 Quantifying Success: Measuring Depth of Treatment Response in MDD

EP. 6 Quantifying Success: Measuring Depth of Treatment Response in MDD

EP. 7 Access Challenges: Bridging Insurance Gaps for MDD Innovations

EP. 7 Access Challenges: Bridging Insurance Gaps for MDD Innovations

EP. 8 Depression Treatment: Expert Guide to Medication Management & Therapeutic Success

EP. 8 Depression Treatment: Expert Guide to Medication Management & Therapeutic Success

EP. 9 From Neuroplasticity to Patient Conversations: Managing Affective Disorders Effectively

EP. 9 From Neuroplasticity to Patient Conversations: Managing Affective Disorders Effectively

EP. 10 Managing Persistent MDD: Case Studies and Treatment Challenges

EP. 10 Managing Persistent MDD: Case Studies and Treatment Challenges

EP. 11 Evaluating Treatment Failure and Symptomatic Remission in MDD

EP. 11 Evaluating Treatment Failure and Symptomatic Remission in MDD

EP. 12 Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution

EP. 12 Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution

EP. 13 Addressing Unsatisfactory Responses in Chronic MDD

EP. 13 Addressing Unsatisfactory Responses in Chronic MDD

EP. 14 Defining and Managing Treatment-Resistant Depression: Efficacy and Real-World Insights

EP. 14 Defining and Managing Treatment-Resistant Depression: Efficacy and Real-World Insights

EP. 15 Optimizing Treatment Response: Insights from Clinical Data and Real-World Experience

EP. 15 Optimizing Treatment Response: Insights from Clinical Data and Real-World Experience

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Concluding Thoughts: Practical Tips, Resources, and More

ByJonathan M. Meyer, MD, DLFAPA

December 8th 2025

A New Option: Getting TDM Data Faster

ByJonathan M. Meyer, MD, DLFAPA

December 1st 2025

Using TDMs to Improve Care and Communication

ByJonathan M. Meyer, MD, DLFAPA

November 20th 2025

Why Therapeutic Drug Monitoring Is Important for Antipsychotics

ByJonathan M. Meyer, MD, DLFAPA

November 13th 2025

1 KOL is featured in this series

Future Directions For Prescription Digital Therapeutics

ByGustavo Alva, MD, DFAPA,Erin Crown, MHS, PA-C, Psych-CAQ,Linda Trinh, DNP, MPH, FNP-C, PMHNP-BC

September 30th 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

FDA Approves ProlivRX: First Prescription, Physician-Directed, At-Home Brain Neuromodulation Therapy for MDD

What Makes It So Special? A Review of the Mechanisms of Action of Lamotrigine, Carbamazepine, and Valproic Acid and How They Differ From Other Antiepileptics

Anticholinergic Burden and Its Effect on Cognition in Psychosis

Progress Report: Second Interim Safety Review of Phase 3 Trial of LPCN 1154 in Postpartum Depression

In Memoriam: The Many Faces of Psychiatrists and Psychiatry